查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1401978

2030 年正子断层扫描市场预测：按产品、应用、最终用户和地区进行的全球分析

Positron Emission Tomography Market Forecasts to 2030 - Global Analysis By Product (Radiotracers, Positron Emission Tomography (PET) Scanners, Radiopharmaceuticals and Other Products), Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据Stratistics MRC预测，2023年全球正子断层扫描市场规模将达15亿美元，预计2030年将达到27亿美元，预测期内复合年增长率为8.6%。

一种称为「正子断层扫描」（PET）的正子医学和生化分析技术用于测量细胞的代谢活动。透过静脉 (IV) 管线将少量放射性葡萄糖（糖）注射到患者的静脉中。 PET 扫描主要用于肿瘤学，对组织中的代谢活动进行影像和评估，有助于识别癌症、分期和监测治疗。 PET 扫描使用放射性追踪剂在分子层面上精确成像生理过程，帮助医生发现问题并评估治疗效果。

根据世界核能会2022年4月的更新，每年约进行4000万次核医学治疗，放射性同位素的需求每年增加高达5%。

癌症发生率上升

对先进诊断设备的需求不断增加，特别是随着老年人癌症发生率的增加。 PET 影像对于肿瘤学至关重要，因为它普及于识别分子层面的代谢活动。提供有关组织代谢过程的广泛知识有助于准确的癌症诊断、分期和监测治疗反应。此外，随着世界各地的卫生系统努力应对不断上升的癌症发生率，PET 扫描是肿瘤学家可以用来根据每位患者的需求调整治疗的重要工具。

资金成本高

PET 扫描器需要大量资金来购买、设定和维护，这使得许多医疗机构（尤其是资源有限的医疗机构）高成本。这种高资本成本是 PET 成像所需的先进技术和专用组件造成的，限制了患者和医疗保健提供者获得 PET 扫描的机会。然而，成本负担超出了最初的购买范围，还包括放射性药物用品、设备维护和合格人员培训的持续支出。

越来越重视个人化医疗

PET 对于医学典范转移至关重要。 PET 影像提供了有关疾病分子特征的重要资讯，使我们能够更好地了解每位患者对治疗的反应。 PET 可以在分子层面观察代谢活动，帮助医生确定最有效的治疗方法并追踪其效果。除了提高诊断准确性之外，这种个体化方法还可以帮助开发更有针对性和更有效的治疗方法，最大限度地减少副作用并最大限度地提高患者的治疗效果。

限制进入迴旋加速器

迴旋加速器中会产生氟 18 等短寿命放射性同位素，对于 PET 成像至关重要。然而，迴旋加速器的取得和可用性通常受到限制，特别是在某些地理区域或医疗机构。迴旋加速器的安装和操作需要昂贵且复杂的基础设施，因此很难在资源有限的地方建立 PET 成像中心。除了阻碍 PET 技术的进一步整合之外，迴旋加速器的使用受限也为确保放射性药物的持续供应带来了后勤困难。

COVID-19 的影响：

由于疫情爆发，卫生服务受到干扰，病毒控制和限製成为当务之急。为了更好地利用资源用于与大流行相关的工作，一些非紧急医疗程序，包括一些诊断成像测试，已被取消或推迟。受此影响，各种疾病的PET检查需求暂时减少。供应链问题、物流困难和病患流动限制进一步限制了 PET 影像服务的取得。卫生系统在应对不断变化的大流行环境时，面临着满足定期维护计划和安装新 PET 设备延迟的挑战。

放射性示踪剂场预计在预测期内达到最大值

预计辐射示踪剂领域在预测期内将是最大的。短寿命放射化学物质或放射性追踪剂是 PET 影像的重要组成部分，可以了解体内的代谢活动。 PET 在肿瘤学、循环系统和神经病学等医学专业中的使用不断增加，导致对各种特定放射性追踪剂的需求不断增长。此外，由于放射性药物的研究和开发，新的追踪剂已被开发出来，提高了诊断准确性并扩大了 PET 成像的应用范围。

预计心臟病学领域在预测期内复合年增长率最高。

预计心臟病学的复合年增长率最高。 PET 影像在心臟病学领域越来越普及，因为它能够提供对心臟代谢和血流的高解析度功能洞察。这项技术对于检测和治疗心肌梗塞和冠状动脉疾病等心血管疾病至关重要。此外，PET 有潜力提供有关心臟功能、活力和灌注的全面资讯，因此在循环系统医学中引起了极大的兴趣。这些资讯有助于医生及时、准确地做出有关患者治疗的决定。

占有率最大的地区

亚太地区占最大占有率。该地区不断扩大的医疗基础设施和不断增加的医疗技术投资支持了 PET 影像的使用。癌症和心臟病等慢性疾病的增加增加了对先进诊断设备的需求，而 PET 是其中的关键组成部分。亚太地区各国政府正在推动采用尖端诊断影像技术，以此作为提高医疗保健品质和可近性的手段。

复合年增长率最高的地区：

由于对精准诊断的需求不断增加以及肿瘤学和先进诊断应用的 PET成像技术的改进等因素，预计北美地区将出现良好的增长。由于前列腺癌和乳腺癌等癌症发病率的增加，预计该地区的市场也将显着增长。例如，美国癌症协会的2022年预测预测，2022年美国将新增1,918,030例癌症病例。

免费客製化服务：

订阅此报告的客户可以利用以下免费自订选项之一：

  • 公司简介
    • 其他市场参与企业的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计/预测/复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 研究资讯来源
    • 主要研究资讯来源
    • 二次研究资讯来源
    • 先决条件

第三章市场趋势分析

  • 介绍
  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第五章全球正子断层扫描市场：按产品

  • 介绍
  • 放射性示踪剂
  • 正子断层扫描 (PET) 扫描仪
  • 放射性药物
  • 其他产品

第六章正子断层扫描的全球市场：依应用分类

  • 介绍
  • 神经病学
    • 阿兹海默症和失智症
    • 脑肿瘤评估
    • 精神障碍
    • 运动障碍
    • 神经感受器成像
  • 心臟病学
    • 冠状动脉疾病评估
    • 发炎成像
    • 心肌灌注显像
    • 动脉粥状硬化成像
    • 心内膜炎的评估
  • 感染疾病研究
  • 肿瘤学
  • 肺部疾病
  • 研究和药物开发
  • 其他用途

第七章全球正子断层扫描市场：依最终使用者分类

  • 介绍
  • 专科诊所
  • 癌症治疗中心
  • 诊断中心
  • 医院
  • 放射中心
  • 其他最终用户

第八章全球正子断层扫描市场：按地区

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 中东和非洲其他地区

第九章 主要进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十章 公司简介

  • GE Healthcare
  • Philips Healthcare
  • Toshiba Corporation
  • Hitachi, Ltd
  • Rigaku Corporation
  • Siemens Healthineers
  • Positron Corporation
  • Medtronic plc
  • PerkinElmer, Inc.
  • Eckert & Ziegler Group
  • Naviscan, Inc.
  • Cubresa Inc
  • Raycan Technology Co., Ltd
  • CMR Naviscan Corporation
  • Navidea Biopharmaceuticals
  • Rotem Industries Ltd
Product Code: SMRC24498

According to Stratistics MRC, the Global Positron Emission Tomography Market is accounted for $1.5 billion in 2023 and is expected to reach $2.7 billion by 2030 growing at a CAGR of 8.6% during the forecast period. A nuclear medicine and biochemical analysis technique called "positron emission tomography" (PET) is used to measure the metabolic activity of cells. Through an intravenous (IV) line, a small quantity of radioactive glucose, or sugar, is injected into the patient's vein. PET scans are mostly utilized in oncology, where they help with cancer identification, staging, and therapy monitoring by allowing the imaging and assessment of metabolic activity in tissues. PET scans help physicians identify problems and evaluate the effectiveness of treatment by providing precise images of physiological processes at the molecular level through the use of radioactive tracers.

According to the World Nuclear Association April 2022 update, around 40 million nuclear medicine procedures are performed each year, and demand for radioisotopes is increasing by up to 5% annually.

Market Dynamics:

Driver:

Rising incidence of cancer

The need for sophisticated diagnostic instruments has increased as cancer incidence is rising, especially in elderly people. PET imaging is vital to oncology because of its popularity for identifying molecular-level metabolic activity. By offering extensive knowledge of the metabolic processes of tissues, it facilitates accurate cancer diagnosis, staging, and therapy response monitoring. Moreover, PET scans are a vital tool that oncologists can use to adapt therapies depending on the needs of each patient as healthcare systems throughout the world grapple with the rising incidence of cancer.

Restraint:

High capital cost

PET scanners have become costly for many healthcare facilities, especially those with limited resources, due to the significant financial outlays required for their purchase, setup, and maintenance. This high capital cost is a result of the sophisticated technology and particular components needed for PET imaging, which restricts the availability of PET scans for patients and healthcare providers. However, the cost burden extends beyond the original purchase and includes continuing expenditures for radiopharmaceutical supply, equipment maintenance, and qualified worker training.

Opportunity:

Growing emphasis on personalized medicine

PET is essential to the paradigm shift in medical care, which is shifting more and more toward customized and tailored therapies. PET imaging offers vital information on the distinct molecular features of diseases, enabling an improved understanding of how each patient will respond to treatment. PET helps doctors identify the most effective treatments and track their effects by allowing them to witness metabolic activity at the molecular level. In addition to improving diagnostic precision, this individualized approach helps develop more focused and effective therapies that minimize adverse effects and maximize outcomes for patients.

Threat:

Limited accessibility of cyclotrons

Short-lived radioisotopes, like fluorine-18, are generated in cyclotrons and are crucial for PET imaging. However, cyclotron accessibility and availability are frequently limited, especially in certain geographical areas or medical facilities. The installation and operation of cyclotrons require expensive and sophisticated infrastructure, which makes it difficult to establish PET imaging centers in places where these resources are limited. In addition to impeding the further integration of PET technology, this restriction on cyclotron accessibility creates logistical difficulties in ensuring an ongoing supply of radiopharmaceuticals.

COVID-19 Impact:

Healthcare services were disrupted as a result of the epidemic, and controlling and restricting the virus gained precedence. Several non-urgent medical procedures-such as certain diagnostic imaging studies-were canceled or postponed in order to use resources more effectively for pandemic-related initiatives. This resulted in a brief decrease in demand for the routine use of PET scans for a variety of medical disorders. PET imaging services' accessibility was further limited by supply chain problems, logistical difficulties, and patient mobility limitations. Healthcare systems faced difficulties adhering to regular maintenance schedules and delays in the installation of new PET equipment as they adjusted to the changing pandemic environment.

The radiotracers segment is expected to be the largest during the forecast period

Radiotracers segment is expected to be the largest during the forecast period. Short-lived radioactive chemicals, or radiotracers, are essential parts of PET imaging that make the body's metabolic activities accessible. The growing need for a variety of specific radiotracers is a result of the growing uses of PET in oncology, cardiology, and neurology, among other medical specialties. Moreover, novel tracers have been developed as a result of developments in radiopharmaceutical research and development, improving diagnostic precision and broadening the application of PET imaging.

The cardiology segment is expected to have the highest CAGR during the forecast period

Cardiology segment is expected to have the highest CAGR. PET imaging is becoming more and more popular in cardiology due to its incredible ability to offer high-resolution, functional insights into heart metabolism and blood flow. When it comes to the detection and treatment of cardiovascular diseases, including myocardial infarction and coronary artery disease, this technology is essential. Moreover, because PET may provide comprehensive information about heart function, viability, and perfusion, it is highly sought after in cardiology. This information helps doctors make timely and precise decisions regarding patient care.

Region with largest share:

Asia Pacific region dominated the largest share. PET imaging use is being aided by the region's expanding healthcare infrastructure and rising medical technology investments. Growing rates of chronic illnesses, such as cancer and heart problems, are driving up the need for sophisticated diagnostic instruments, of which PET is an essential component. Governments around Asia-Pacific are promoting the incorporation of cutting-edge imaging technologies as a means of enhancing healthcare quality and accessibility.

Region with highest CAGR:

Due to factors including the growing need for precision diagnostics and the technological improvements in PET imaging for oncology and advanced diagnostic applications, the North American region is projected to have lucrative growth. Significant market growth in the region is also anticipated due to the increasing incidence of cancer cases, including prostate and breast cancer. For instance, according to the American Cancer Society's 2022 forecast, 1,918,030 new cases of cancer are expected in the United States in 2022.

Key players in the market:

Some of the key players in Positron Emission Tomography market include GE Healthcare, Philips Healthcare, Toshiba Corporation, Hitachi, Ltd, Rigaku Corporation, Siemens Healthineers, Positron Corporation, Medtronic plc, PerkinElmer, Inc., Eckert & Ziegler Group, Naviscan, Inc., Cubresa Inc, Raycan Technology Co., Ltd, CMR Naviscan Corporation, Navidea Biopharmaceuticals and Rotem Industries Ltd.

Key Developments:

In August 2022, Positron Corporation, a nuclear medicine PET imaging device system and clinical services company, purchased its first PET-CT system and was on its way from its partner Neusoft Medical Systems. Positron's "Affinity PET-CT" system is on its way from China to its validation partner in the United States.

In July 2022, Radialis Inc. received clearance to market the Radialis PET Imager, an organ-targeted positron emission tomography (PET) system, in the United States. The advanced sensitivity of the Radialis PET Imager to radiotracer enables the system to produce functional images with high spatial resolution, expanding the insight available from molecular imaging.

Products Covered:

  • Radiotracers
  • Positron Emission Tomography (PET) Scanners
  • Radiopharmaceuticals
  • Other Products

Applications Covered:

  • Neurology
  • Cardiology
  • Infectious Diseases
  • Oncology
  • Pulmonary Disorders
  • Research and Drug Development
  • Other Applications

End Users Covered:

  • Specialty Clinics
  • Cancer Treatment Centers
  • Diagnostic Centers
  • Hospitals
  • Radiology Centers
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Positron Emission Tomography Market, By Product

  • 5.1 Introduction
  • 5.2 Radiotracers
  • 5.3 Positron Emission Tomography (PET) Scanners
  • 5.4 Radiopharmaceuticals
  • 5.5 Other Products

6 Global Positron Emission Tomography Market, By Application

  • 6.1 Introduction
  • 6.2 Neurology
    • 6.2.1 Alzheimer's Disease and Dementia
    • 6.2.2 Brain Tumor Evaluation
    • 6.2.3 Psychiatric Disorders
    • 6.2.4 Movement Disorders
    • 6.2.5 Neuroreceptor Imaging
  • 6.3 Cardiology
    • 6.3.1 Coronary Artery Disease Evaluation
    • 6.3.2 Inflammation Imaging
    • 6.3.3 Myocardial Perfusion Imaging
    • 6.3.4 Atherosclerosis Imaging
    • 6.3.5 Endocarditis Evaluation
  • 6.4 Infectious Diseases
  • 6.5 Oncology
  • 6.6 Pulmonary Disorders
  • 6.7 Research and Drug Development
  • 6.8 Other Applications

7 Global Positron Emission Tomography Market, By End User

  • 7.1 Introduction
  • 7.2 Specialty Clinics
  • 7.3 Cancer Treatment Centers
  • 7.4 Diagnostic Centers
  • 7.5 Hospitals
  • 7.6 Radiology Centers
  • 7.7 Other End Users

8 Global Positron Emission Tomography Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 GE Healthcare
  • 10.2 Philips Healthcare
  • 10.3 Toshiba Corporation
  • 10.4 Hitachi, Ltd
  • 10.5 Rigaku Corporation
  • 10.6 Siemens Healthineers
  • 10.7 Positron Corporation
  • 10.8 Medtronic plc
  • 10.9 PerkinElmer, Inc.
  • 10.10 Eckert & Ziegler Group
  • 10.11 Naviscan, Inc.
  • 10.12 Cubresa Inc
  • 10.13 Raycan Technology Co., Ltd
  • 10.14 CMR Naviscan Corporation
  • 10.15 Navidea Biopharmaceuticals
  • 10.16 Rotem Industries Ltd

List of Tables

  • Table 1 Global Positron Emission Tomography Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Positron Emission Tomography Market Outlook, By Product (2021-2030) ($MN)
  • Table 3 Global Positron Emission Tomography Market Outlook, By Radiotracers (2021-2030) ($MN)
  • Table 4 Global Positron Emission Tomography Market Outlook, By Positron Emission Tomography (PET) Scanners (2021-2030) ($MN)
  • Table 5 Global Positron Emission Tomography Market Outlook, By Radiopharmaceuticals (2021-2030) ($MN)
  • Table 6 Global Positron Emission Tomography Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 7 Global Positron Emission Tomography Market Outlook, By Application (2021-2030) ($MN)
  • Table 8 Global Positron Emission Tomography Market Outlook, By Neurology (2021-2030) ($MN)
  • Table 9 Global Positron Emission Tomography Market Outlook, By Alzheimer's Disease and Dementia (2021-2030) ($MN)
  • Table 10 Global Positron Emission Tomography Market Outlook, By Brain Tumor Evaluation (2021-2030) ($MN)
  • Table 11 Global Positron Emission Tomography Market Outlook, By Psychiatric Disorders (2021-2030) ($MN)
  • Table 12 Global Positron Emission Tomography Market Outlook, By Movement Disorders (2021-2030) ($MN)
  • Table 13 Global Positron Emission Tomography Market Outlook, By Neuroreceptor Imaging (2021-2030) ($MN)
  • Table 14 Global Positron Emission Tomography Market Outlook, By Cardiology (2021-2030) ($MN)
  • Table 15 Global Positron Emission Tomography Market Outlook, By Coronary Artery Disease Evaluation (2021-2030) ($MN)
  • Table 16 Global Positron Emission Tomography Market Outlook, By Inflammation Imaging (2021-2030) ($MN)
  • Table 17 Global Positron Emission Tomography Market Outlook, By Myocardial Perfusion Imaging (2021-2030) ($MN)
  • Table 18 Global Positron Emission Tomography Market Outlook, By Atherosclerosis Imaging (2021-2030) ($MN)
  • Table 19 Global Positron Emission Tomography Market Outlook, By Endocarditis Evaluation (2021-2030) ($MN)
  • Table 20 Global Positron Emission Tomography Market Outlook, By Infectious Diseases (2021-2030) ($MN)
  • Table 21 Global Positron Emission Tomography Market Outlook, By Oncology (2021-2030) ($MN)
  • Table 22 Global Positron Emission Tomography Market Outlook, By Pulmonary Disorders (2021-2030) ($MN)
  • Table 23 Global Positron Emission Tomography Market Outlook, By Research and Drug Development (2021-2030) ($MN)
  • Table 24 Global Positron Emission Tomography Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 25 Global Positron Emission Tomography Market Outlook, By End User (2021-2030) ($MN)
  • Table 26 Global Positron Emission Tomography Market Outlook, By Specialty Clinics (2021-2030) ($MN)
  • Table 27 Global Positron Emission Tomography Market Outlook, By Cancer Treatment Centers (2021-2030) ($MN)
  • Table 28 Global Positron Emission Tomography Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
  • Table 29 Global Positron Emission Tomography Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 30 Global Positron Emission Tomography Market Outlook, By Radiology Centers (2021-2030) ($MN)
  • Table 31 Global Positron Emission Tomography Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.